Swing Therapeutics closes $10.3M Series A funding

Swing TherapeuticsThe Series A funding for, a San Francisco, CA-based company that specializes in digital therapeutics, was $10.3M. Jazz Venture Partners led the round with participation from Asahi Kasei Corporate Ventures and Asahi Kasei Alumni Ventures. The company intends to use the funds to support the execution of the PROSPER-FM randomized clinical trial and to launch an affiliated telemedicine clinic. Swing Therapeutics, headed by Mike Rosenbluth, is creating digital treatments and services for patients in diseases that aren’t well-served. It focuses on treating autoimmune conditions as well as chronic overlapping pain conditions (COPCs), such as fibromyalgia, where central pain sensitization plays a significant role. FDA Breakthrough Device Designation was granted to the company in recognition of its digital therapy for managing fibromyalgia. Its goal in the near term is to validate its digital treatment and bring it on-board as an FDA-cleared digital prescription therapeutic. PROSPER-FM is studying the effectiveness of two treatment options for fibromyalgia. These are Digital Acceptance and Commitment Therapy, a form cognitive behavioral therapy, and a Digital Symptom Tracker. Swing’s Digital ACT program is a daily-use digital therapeutic that includes engaging lessons and interactive exercises that help patients apply ACT principles to their unique circumstances and improve their ability to manage their condition over time. Swing’s Digital Symptom Tracker is a daily use digital therapeutic that includes common pain management approaches including monitoring daily symptoms over time and access to fibromyalgia and general health education.